- Home
- CNMD vs MESO Comparison
CNMD vs MESO Comparison
Compare CNMD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- MESO
- Stock Information
- Founded
- CNMD 1970
- MESO 2004
- Country
- CNMD United States
- MESO Australia
- Employees
- CNMD N/A
- MESO N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNMD Health Care
- MESO Health Care
- Exchange
- CNMD Nasdaq
- MESO Nasdaq
- Market Cap
- CNMD 1.7B
- MESO 1.7B
- IPO Year
- CNMD 1987
- MESO N/A
- Fundamental
- Price
- CNMD $48.59
- MESO $10.72
- Analyst Decision
- CNMD Buy
- MESO Buy
- Analyst Count
- CNMD 5
- MESO 4
- Target Price
- CNMD $77.20
- MESO $18.00
- AVG Volume (30 Days)
- CNMD 536.8K
- MESO 240.4K
- Earning Date
- CNMD 04-30-2025
- MESO 02-26-2025
- Dividend Yield
- CNMD 1.65%
- MESO N/A
- EPS Growth
- CNMD 108.33
- MESO N/A
- EPS
- CNMD 4.25
- MESO N/A
- Revenue
- CNMD $1,307,015,000.00
- MESO $5,670,000.00
- Revenue This Year
- CNMD $5.97
- MESO $228.57
- Revenue Next Year
- CNMD $5.63
- MESO $356.77
- P/E Ratio
- CNMD $11.43
- MESO N/A
- Revenue Growth
- CNMD 5.00
- MESO N/A
- 52 Week Low
- CNMD $47.25
- MESO $4.60
- 52 Week High
- CNMD $78.58
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- CNMD 32.11
- MESO 38.38
- Support Level
- CNMD $47.25
- MESO $10.26
- Resistance Level
- CNMD $57.17
- MESO $11.33
- Average True Range (ATR)
- CNMD 3.25
- MESO 0.75
- MACD
- CNMD -0.81
- MESO 0.06
- Stochastic Oscillator
- CNMD 9.65
- MESO 37.37
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.